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Abstract
The formation of new neurons continues into adult life in the dentate gyrus of the rat hippocampus, as in many other
species. Neurogenesis itself turns out to be highly labile, and is regulated by a number of factors. One of these is the
serotoninergic system: treatment with drugs (such as the SSRI fluoxetine) markedly stimulates mitosis in the progenitor cells
of the dentate gyrus. But this process has one remarkable feature: it takes at least 14 days of continuous treatment to be
effective. This is despite the fact that the pharmacological action of fluoxetine occurs within an hour or so of first
administration. This paper explores the role of BDNF in this process, using the effect of a Trk antagonist (K252a) on the
labelling of progenitor cells with the mitosis marker Ki67 and the associated expression of pCREB and Wnt3a. These
experiments show that (i) Fluoxetine increased Ki67 counts, as well as pCREB and Wnt3a expression in the dentate gyrus.
The action of fluoxetine on the progenitor cells and on pCREB (but not Wnt3a) depends upon Trk receptor activation, since
it was prevented by icv infusion of K252a. (ii) These receptors are required for both the first 7 days of fluoxetine action,
during which no apparent change in progenitor mitosis occurs, as well as the second 7 days. Increased pCREB was always
associated with progenitor cell mitosis, but Wnt3a expression may be necessary but not sufficient for increased progenitor
cell proliferation. These results shed new light on the action of fluoxetine on neurogenesis in the adult dentate gyrus, and
have both clinical and experimental interest.
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Introduction
The realisation that neurogenesis continues in the dentate gyrus
into adult life has aroused considerable interest for several reasons.
The functional significance of a generative and restorative process,
more typical of the developing brain, in this region of the adult
remains enigmatic. It has also raised hopes that a similar process
might be inducible in other areas following damage or malfunction.
A number of attempts, some more convincing than others, have
beenmade to show that inhibiting neurogenesis - a procedurewhich
has technical problems related to its specificity - reduces mnemonic
abilities [1,2,3,4] though precisely why this should require newly-
formedneuronsisstilldebated[5,6].Thereisthesuggestionthatthe
onset of depression in humans, or its response to treatment with
antidepressants, may be related in some way to altered neurogenesis
in the dentate gyrus[7,8,9].Direct evidence for this hypothesis is still
scanty and conflicting [10,11]. However, there is no doubt that
some drugs used as anti-depressants – such as fluoxetine - stimulate
neurogenesis, particularly the mitotic rate of the progenitor cells.
Chronic, but not acute, treatment of rats with fluoxetine, a
typical SSRI (Selective Serotonin Reuptake Inhibitor), stimulates
the proliferative rate of the progenitor cells lining the internal layer
of the dentate gyrus [12]. This takes around 14 days, which is
intriguing since the pharmacological action of this drug begins
within hours. These finding suggests that there are downstream
actions upon which the proliferativc action of these drugs depends.
This latent period recalls the similar one preceding therapeutic
effects in patients treated for depression. Santarelli and colleagues
reported that suppression of neurogenesis either by radiation or
5HT1A receptor knockout prevented the ameliorating actions of
fluoxetine on novelty suppressed feeding [13]. Although this was
hailed as support for a link between hippocampal neurogenesis
and depression, the behavioural test had more to do with anxiety
than depression, and a further study (from the same group) using a
different test (forced swim) and a different strain of mouse failed to
replicate it [14]. Nevertheless, the necessity for prolonged
treatment with drugs such as fluoxetine for both behavioural
and cytological actions remains to be explained.
BDNF (Brain-Derived Neurotrophic Factor) is involved in
activity dependent neuroplasticity, survival and differentiation in
both the periphery and CNS. The BDNF-responsive TrkB
(Tropomyosin-associated kinase) receptors upregulate or down-
regulate many second messengers that lead to the phosphorylation
of transcriptional factors such as CREB (c-AMP response element-
binding). Chronic antidepressant treatment stimulates pCREB
though there have been conflicting reports[15,16,17]. Previous
studies have also shown that there are increased levels of BDNF
protein and mRNA in rat treated with antidepressants [16,18,19].
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signalling in the brain have provided evidence that TrkB activation
is required for the behavioural actions typically induced by
antidepressants [20]. Wnt signalling has been implicated in both
embryonicandadult neurogenesis[21,22],butwhetheritisinvolved
in the action of fluoxetine on adult neurogenesis is not known.
We have addressed the question of the importance of TrkB
receptor activation on antidepressant effect on cell mitosis and on
the latent period preceding activation of progenitor cell mitosis.
The first experiment determines whether intracerebroventricular
(icv) infusion of the Trk antagonist K252a, can block the action of
fluoxetine (10 mg/kg/day) on progenitor cell mitosis, and the
effect it has on the expression of pCREB and Wnt3a in the
granular neurons in the dentate gyrus. The second explores
whether rats treated with the same dose of fluoxetine for 7 days
show any change in progenitor proliferation, or expression of
pCREB or Wnt3a, compared to those treated for 14 days. Then
the role of the Trk receptors in the latent period required for
fluoxetine to act was investigated by giving K252a for either the
first or second 7 days of the 14 day treatment period.
Materials and Methods
Animals
Allprocedures werecarried outunder Home Office(UK) licence.
Male Sprague-Dawley rats 8 weeks old (Harlan, Oxon, UK) were
used, weighing 200–250 grams at the start of the experiment. Rats
were housed individually in a controlled environment. Ambient
temperature was maintained at 21uC and humidity at 55% with ad
libitum access to food and tap water. Animals were kept in a reversed
12-h light:12-h dark cycle, (lights off at 10.00 h).
Cannula placement
Animals were anesthetised with isofluorane, oxygen and NO
and placed securely into a stereotaxic frame (David Kopf
instruments, Tujunga,CA, USA). A cannula (length 5 mm, outside
diameter 0.36 mm; (Charles River, Margate, UK) was implanted
into the right lateral ventrical. Coordinates were 1 mm posterior
and 1.5 mm lateral from bregma, 23.3 mm from the cortex
[23].The cannula were fixed in place by dental cement attached to
three stainless steel screws inserted into the skull. They were
connected to an Alzet osmotic minipumps (model 1002; volume
100 ml, flow rate 0.25 ml/h; (Charles River, Margate, UK) via
medical grade vinyl tubing (8 cm length, except in Experiment 2).
All pumps were implanted subcutaneously in the posterior upper
thorax. The pumps and the tubing had been filled the day before
surgery with either K252a (Merck Chemicals, Boulevard Indus-
trial Park, Nottingham) (59.05 ng/day) [24].or saline and
incubated at 37uC overnight in a sterile saline solution to prime
them before implantation. The position of each cannula was
assessed post-mortem by examining its track on sections stained
with cresyl violet (Sigma, UK).
Experimental groups
Experiment 1: The effect of K252a on the response to
fluoxetine. There were four groups (n=6 per group). All were
implanted with Alzet osmotic mini pumps subcutaneously (model
2ML2; volume 2 ml, flow rate 5 ml/h; Charles River,
Margate,UK). In two groups, the pumps delivered fluoxetine
(10 mg/kg/day dissolved in saline) for 14 days; in the other two,
saline alone. All were also implanted with an icv cannula (right
lateral ventricle) connected to a smaller subcutaneous mini-pump
(model1002) (see above). One each of the fluoxetine and saline-
treated groups received icv K252a 59.05 ng/day[24] for 14 days;
the others, saline. The position of each cannula was assessed post-
mortem by examining its track on sections stained with cresyl
violet (Sigma, UK). All animals were killed on day 15, the brains
removed and snap-frozen and placed in 270uC until they were
sectioned later. Sections were stained for Ki-67, BDNF and TrkB
mRNA by in situ hybridisation, and immunofluorescent for
pCREB and Wnt3a proteins.
Experiment 2. Blockade of Trk receptors during the
initial or later stage of the response to fluoxetine. Two
experiments were carried out. In the first, rats (n=5 per group)
were treated either with fluoxetine (10 mg/kg/day) or saline
delivered from osmotic minipumps subcutaneously and killed after
either 7 or 14 days. Brains were examined for Ki67, pCREB,
BDNF and Wnt3a.
In the second, there were four groups (n=6 per group). All
animals received 10 mg/kg/day fluoxetine for 14 days delivered
from osmotic minipumps subcutaneously, as above. All were also
implanted with a second osmotic minipump, connect to an icv
cannula (as above). Through this cannula they received the
following treatments: (i) saline 14 days (ii) K252a for 14 days (as
above) (iii) K252a for the first 7 days, saline for the second 7 days
(iv) saline for the first 7 days, K252a for the second 7 days. The
osmotic minipumps were attached to the tube 11.3 cm long and a
volume of 3.74 ml/cm (ID 0.69 mm). Since flow is 6 ml/day, the
tube will empty by day 7. This was checked in vitro at 37uC. In
group (ii) both tubing and pump were filled with K252a; in group
(iii) the tubing contained K252a, and the pump saline only; this
was reversed in group (iv). All animals were killed on day 15 and
the brains were snap frozen and placed in 270uC until they were
sectioned (as above). Sections were stained for Ki-67.
Brain sections
Brains were sectioned in the coronal plane at 20 mm. The brain
from each rat was sampled from 22.80 to 24.52 behind bregma.
Sections were cut at 220uC using a Bright cryostat, and every
sixth section was mounted on a polylysine-coated microscopic
slide, six to a slide. The slides were left in a fume hood to dry
overnight, then stored at 270uC. For each rat twelve sections
through the dorsal hippocampus were analyzed 120 mm apart (ie
one in six sections) for Ki-67 staining.
Immunohistochemistry
Ki67. Sections were incubated in 0.01 M citric acid for
40 min at 98uC. They were cooled and washed twice 65 min in
KPBS. Endogenous peroxidase activity was quenched with 3%
H2O2 solution for 10 min followed two 5 min washes with KPBS.
They were incubated with primary antibody (1:100 mouse
monoclonal IgG anti-human Ki-67; Novocastra, Newcastle
Upon Tyne, UK) and 1% horse serum in a humidified chamber
at room temperature overnight. The next day, after twice 65 min
washes with KPBS, they were incubated with secondary antibody
(1:200 biotinylated mouse IgG; Vector laboratories Ltd,
Peterborough UK) for 1 hour at room temperature. After twice
65 min washes with KPBS, they were incubated with Avidin-
Biotin-Peroxidase reagent (Vector laboratories Ltd, Peterborough
UK) for a further hour, followed by twice 65 min washes with
KPBS. The staining was visualized using DAB tablets (3,3-
diaminobenzidin) (Sigma, Dorset, UK) for 5 min. Slides were then
counterstained with 10% crystal violet solution followed by
dehydration through ethanol and Histoclear. They were cover-
slipped with DPX for light microscopy at 640 magnification.
pCREB and Wnt3a. Three sections from each animal (1 in
12; between bregma 23.14 mm and 23.30 mm) were incubated
in rabbit anti pCREB (Cell Signaling, Hitchen, UK; 1:25 in 0.5%
BDNF and Neurogenesis
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room temperature. After two washes with KPBS, the sections were
incubated in Alexa Fluor 568 (Invitrogen, Paisley UK) goat anti
rabbit (1:200 in 0.5% Triton) for one hour, washed twice with
KPBS, and cover slipped.
For single staining with Wnt3a, sections were incubated in rabbit
anti Wnt3a (Abcam, Science Park, Cambridge UK; 5 ug/ml in
0.5% Triton with 1% goat serum) overnight in a humidified
chamber at room temperature. The following day, after two washes
withKPBS, they were incubated in Alexa Fluor 568 goat anti rabbit
(1:200 in 0.5% Triton) for one hour, and washed twice with KPBS
and covered slipped.
BDNF mRNA in situ hydridisation
Sections were allowed to air dry at room temperature and were
then fixed with 4% paraformaldehyde (Sigma, Dorset, UK) for
5 min, washed inPBS and then dehydrated in 70% ethanol and 95%
ethanol for 5 min before final storage in fresh 95% ethanol. In situ
hybridization was carried out under RNAase-free conditions. The
synthetic antisense oligonucleotide probe was confirmed by BLAST
searches. A 48 base and a 45 base oligonucleotide complementary to
exonic mRNA encoding BDNF mRNA [25]. 59 agt tcc agt gcc ttt tgt
cat gcc cct gca gct tcc ttc gtg taa ccc 93 was used. All probes were end-
labelled with
35S-ATP as follows: 2 ml of purified oligonucleotide
(5 ng/ml) was added to 1.25 mlB u f f e ra n d1 . 2 5ml cobalt chloride
(New England, Biosystem, UK). DEPC (Diethyl pyrocarbonate
Sigma,Dorset,UK)-treatedwater(6.5 ml)wasadded,followedby1 ml
terminal 35S deoxyadenosine 59 (a-thio) triphosphate (10 mCi/ml)
(Amersham, Buckinghamshire, UK) and 0.5 ml (15–20 U) terminal
deoxynucleotide transferase enzyme (New England, Biosystem UK).
Probes were incubated at 37uC for 1 h before 40 mlo fD E P Cw a s
added to terminate the reaction. Purification of labelled probe from
unincorporated nucleotides was accomplished by centrifugation
through a G-50 Sephadex micro-column (Amersham, UK). Probes
were evaluated for incorporation of radiolabel by scintillation
counting. All hybridizations were carried out at 2500–5000 cpm/ml
in hybridization buffer (50% deionized formamide, 46 SSC, 56
Denhardt’s,100 mg/ml polyadenylic (potassium salt) acid, 200 mg/ml
salmon sperm DNA, 120 mg/ml heparin (BDH, Leicestershire, UK),
25 mM sodium phosphate pH 7.0,1 mM sodium pyrophosphate,
10% (w/v) dextran sulphate in DEPC–treated water (all Sigma
Dorset, UK). Sections were covered with parafilm and hybridized
o v e r n i g h ta t4 4 uC in a humid atmosphere. Excess unbound probe
was removed using the following washes: 16 SSC (saline sodium
citrate, Sigma, UK) at room temperature, 2630 min at 55uCw i t h
16 SSC and then rinsed at room temperature for 2 min, each in
16 SSC, 0.16 SSC, 18 V water, 50%, 70%, and 95% ethanol
(BDH. Leicestershire, UK).
Sections were exposed to autoradiographic X-ray film (Amer-
sham, Buckinghamshire, UK) for 14 days. Sense probes were run
as negative controls.
Quantification
Proliferating cells (Ki67). All slides were randomised and
coded prior to quantitative analysis.
Labelled cells were counted using a 40X objective; only cells on
the internal border of the subgranular zone of the dentate gyrus
were included. The data shown are the mean number of Ki67-
labelled cells per section from 12 sections per animal.
BDNF mRNA expression. Sections and C
14 labeled
standards of known radioactivity (Amersham, Buckinghamshire,
UK) were placed in X-ray cassettes and exposed to
autoradiographic film. The optical density (OD) of the
autoradiographic images was measured using a computerized
PC-based image analysis system (NIH Image). ODs from the
dentate gyrus from three consecutive sections per rat were
obtained and averaged. The mean value for each rat was
entered into the equation derived from the C
14 standards and
the final value were used to calculate group means. Sections from
all groups were processed at the same time to avoid intrinsic
variations between different in situ hybridizations.
Statistical analysis
Between-group one/two-way analysis of variance (ANOVA)
and Bonferroni’s post hoc test were used when applicable. Log
transformation was used to ensure homogeneity of variance before
ANOVA when appropriate. Results were considered statistically
significant if p,0.05.
Results
Experiment 1: Effect of K252a on the response of
progenitor cells to fluoxetine
In this experiment, we tested whether blockade of the Trk
receptor by icv K252a would prevent the stimulating action of
fluoxetine on mitosis in the neurogenic area of the dentate gyrus.
Ki-67. Ki67 positive cells were found in the SGZ of all
animals including controls, confirming the presence of a basal level
of progenitor cell mitosis in this region. There was a significant
interaction between fluoxetine and K252a treatments (Two-way
ANOVA, F (1,20)=36.7, p,0.001). Icv K252a alone had no
effect on the number of proliferating cells (Bonferroni, p.0.05).
10 mg/kg/day fluoxetine increased the number of proliferating
cells by 88% (p,0.001) (Figure 1A). This effect was completely
blocked by K252a (p.0.05). The number of Ki67-labelled cells in
this group was not significantly different from the controls group
(p.0.05), but was significantly less than after fluoxetine treatment
alone (p,0.005) (Figure 1A).
BDNF mRNA. K252a alone had no effect (F=0.28; p:ns).
Fluoxetine increased levels, as expected (F=34.6. p,0.0001), but
this was not prevented by simultaneous infusion of K252a; there
was thus no significant interaction between K252a and fluoxetine
(F=2.4, p:ns) (Figure 1B).
pCREB. Saline-treated animals showed little expression of
pCREB protein in the dentate gyrus. This was markedly
stimulated by fluoxetine treatment. K252a-treated animals
showed a similar picture to the saline-treated group (Figure 1C).
Adding K252a to fluoxetine resulted in reduced pCREB
expression which now resembled animals treated with saline.
Wnt3a. Saline-treated animals showed little expression of
Wnt3a protein in the dentate gyrus (Figure 1D). This was
markedly stimulated by fluoxetine treatment. K252a-treated
animals showed a similar picture to the saline-treated group.
However, adding K252a to fluoxetine did not prevent the latter’s
stimulating effect on Wnt3a expression (Figure 1D).
In summary: this experiment showed that icv K252a prevented
the stimulating effect of fluoxetine on progenitor mitosis in the
dentate gyrus, but did not prevent increased BDNF mRNA. There
was a selective action of K252a on inhibiting the effect of
fluoxetine on pCREB but not Wnt3a.
Experiment 2: Effect of treatment with K252a for either
the first or second 7 days of a 14 day fluoxetine
treatment
Since fluoxetine treatment is required for at least 14 days to
increase progenitor cell mitosis rates, we asked whether activation
of Trk receptors was required for the whole of this period.
BDNF and Neurogenesis
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expected after 14 days of fluoxetine treatment (Figure 2A).
However, at 7 days there was no difference between fluoxetine
and control groups (two-way ANOVA: fluoxetine6time F=14.0,
p=0.002).
BDNF. BDNF mRNA expression showed a similar pattern.
Expression increased after 14 days in the fluoxetine-treated group,
but not 7 days, (F=150, p,0.001) (Figure 2B). Pairwise
comparisons showed that BDNF levels at 7 days were no
different between the fluoxetine-treated and control groups
(Bonferroni, p.0.05) but that fluoxetine treatments at 7 and 14
days were significantly different from each other (p,0.001)
(Figure 2E, F).
pCREB and Wnt3a. There was also no observable change in
either pCREB or Wnt3a at 7 days, but by 14 days the expression
of both was clearly increased (Figure 2C, D).
Ki-67. In the second part of this experiment, as expected from
Experiment 1, icv K252a for 14 days reduced Ki67 positive cells
expression in 14-day fluoxetine -treated rats compared to those
receiving fluoxetine and icv saline (One-way ANOVA: F (3,15)
=63.8, p,0.001. Pairwise comparison: (Bonferroni) p,0.001).
However, K252a infusions for either the first or second 7 days also
reduced the effect of 14 days fluoxetine treatment, and there was
no difference between the two 7-day treatment periods
(Bonferroni, p.0.05) There was also no difference between
either 7-day and 14 day K252a treatment (Bonferroni, p.0.05)
(Figure 3A). As in Experiment 1, pCREB expression was inhibited
by 14 days K252a treatment (not shown in Figure 3, since there
was effectively no signal in the K252a treated animals) but Wnt3a
expression was not altered, even though Ki67 expression was
reduced (Figure 3B).
In summary. The first part of this experiment showed that 7
days treatment with fluoxetine had no effect on Ki67 labelled cells,
or on the expression of either pCREB or Wnt3a. However, all
three were accentuated after 14 days treatment. The second part
showed that blocking Trk receptors with icv K252a for either the
first of second 7 day period of a 14 day fluoxetine infusion
prevented the expected increase in progenitor cell mitosis. As in
experiment 1, pCREB was reduced in fluoxetine and K252a-
treated animals, but increased expression of Wnt3a still occurred
in fluoxetine-treated animals given K252a.
Table 1 summarises the results of these two experiments on the
expression of Ki67, pCREB and Wnt3a in the dentate gyrus.
Discussion
These experiments further define the role of BDNF in the
regulation of the mitosis rates of progenitor cells in the dentate
gyrus by serotonin-acting drugs such as fluoxetine. Progenitor
mitosis rates are the essential first step in the overall control of
neurogenesis in the adult hippocampus, since they determine its
early stages. Other factors then regulate the differentiation,
survival and connectivity of newly-formed neurons [26]. Labelling
cells with Ki67 is now well established as a reliable indicator of
progenitor cell mitosis in the dentate gyrus, and is highly
correlated with BrdU uptake [27]. The first experiment reported
here established that blockade of Trk receptors by the drug K252a
was able to prevent entirely the stimulating action of fluoxetine on
mitosis of the progenitor cells. The K252 family of alkaloid toxins
are protein kinase inhibitors, and K252a has a long history of
being used to antagonise Trk receptors, with particular affinity for
TrkB [28,29,30]. Icv K252a has already been shown to prevent
Figure 1. The effect of K252a icv on the mitosis rates (Ki67) of progenitor cells in the dentate gyrus. A: Mean number per section after
14 days treatment with either fluoxetine (10 mg/kg/day) sc, K252a icv, or both compared to controls (saline sc and icv). Values are means 6 SEM. C,D:
Photomicrographs of the expression of pCREB and Wnt3a after the four treatments. Bar represents a distance of 100 mm. B; BDNF mRNA in the
dentate gyrus following the same treatment. Values are mean 6SEM. *P,0.05, **p,0.001 compared to control.
doi:10.1371/journal.pone.0013652.g001
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administration [31], but there has been no report on its ability
to inhibit SSRI-induced progenitor cell mitosis. Although we
cannot be entirely certain that our results reflect specific blockade
of TrkB, the accumulative evidence points strongly in this
direction.
K252a did not prevent the fluoxetine-induced increase in
BDNF mRNA expression, suggesting that this is upstream of the
action of TrkB receptors, as might be expected. However, the
results on pCREB were clear-cut: fluoxetine increased its
expression and thiswas prevented by K252a. Since increased
pCREB may be an essential step in the up-regulation of progenitor
mitosis [32], it is interesting that this occurred not just in the cells
adjacent to the neurogenetic niche in the inner layer, but
throughout the dentate gyrus. This suggests that the function of
CREB in the dentate gyrus may be more complex than was
originally thought, and that cells other than those in the
neighbourhood niche may also contribute to the control of
neurogenesis [7]. In contrast, the expression of Wnt3a, also known
to be closely involved in neurogenesis [3,22,33,34] was, as
expected, increased by fluoxetine, but this was not prevented by
K252a. This experiment therefore shows that functional activity of
Trk, and hence – it may be presumed – BDNF is essential for the
stimulating action of fluoxetine on progenitor cell mitosis. This
agrees with results on BDNF-knockout mice, in which SSRIs and
similar drugs have reduced actions [35,36]. However, these studies
were limited to heterozygous knock-outs only, since homozygous
ones do not survive. It is interesting that K252a by itself did not
decrease progenitor mitosis below baseline: this may reflect the
fact that its blockade of TrkB may have been incomplete, or that
BDNF is required only for above-basal proliferation rates. K252a
also blocked the fluoxetine-induced expression of pCREB,
supporting the role for this compound in the control of
neurogenesis. However, it did not prevent increased Wnt3a
expression, suggesting that the latter is not a sufficient event for
increased progenitor cell mitosis.
The second experiment began by confirming, under our
conditions, that a 7-day treatment with fluoxetine had no
discernible effect on progenitor mitosis, or pCREB and Wnt3a
expression, whereas after 14 days all three were stimulated. We
use osmotic minipumps to deliver fluoxetine, since we (and some
others) find that parenteral injections are not effective [37,38].
The striking result, however, was that blocking TrkB for either the
first or the second 7 days of a 14 day treatment with fluoxetine
prevented increased progenitor mitosis. It is during the second
period that BDNF mRNA expression is increased, so it might
seem logical that blockade only during this time would prevent the
BDNF-dependent action of fluoxetine. Had this occurred it would
have implied that the latent period preceding the onset of
fluoxetine’s action was due to some event upstream of the action
of BDNF. But this was not the case. It seems clear that BDNF is
required throughout the latent period, though future experiments
Figure 2. The effect of either 7 or 14 days treatment with fluoxetine (10 mg/kg/day). A: Ki67 cell counts, B: BDNF mRNA expression,
C: pCREB D: Wnt3a. E,F: in situ hybridization images of BDNF mRNA. Values as in Figure 1. Bar represents 100 mm. Values are mean 6SEM.**p,0.001
compared to control. Representative sections are shown from fluoxetine-treated animals only, since there is virtually no expression in controls.
doi:10.1371/journal.pone.0013652.g002
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points. Despite the fact that BDNF mRNA was increased only
after 14 days of fluoxetine treatment, blocking its action at a time
when there was no discernible change in BDNF mRNA prevented
not only the expected increase in progenitor mitosis, but also that
in pCREB, presumably a more proximal regulator of neurogen-
esis. The conclusion must be that BDNF may be active
throughout the latent period. However, we have shown previously
that icv infusions of BDNF are effective after 7 days [39], so the
latent period is not due to a delayed response to BDNF. Our
experiments do not yet allow us to offer a precise explanation of
these results, but there may be two processes. The first, dependent
on ‘basal’ BDNF, may represent one that, in some way, allows
increased BDNF to occur at some time after 7 days from
initiation. The second part of this process may depend on
heightened BDNF production, and it is this that results in
increased pCREB expression, and thus enhanced progenitor
mitosis. Some part of this whole process is highly sensitive both to
the absolute levels of corticoids as well as their circadian pattern
[26,39,40,41,42].
Our results suggest that the expression of pCREB is
downstream of the action of BDNF, since it was prevented by
K252a. Since CREB has a range of intracellular actions, these
may not all link with Wnt3a. Wnt3a has been implicated in the
ability of human neural progenitors to form neurospheres in
culture [33] and in the process of adult neurogenesis, though its
exact role is still unclear [43,44]. Our results suggest that factors
additional to Wnt3a (maybe other members of the Wnt family)
may be needed to increase progenitor cell mitosis rates. Table 1
shows that, whilst we find a consistent association between pCREB
and increased mitosis, this was not true for Wnt3a. However,
increased Wnt3a may be an essential ingredient of the stimulatory
process, since we never observed one without the other, and
inhibition of Wnt signalling reduces adult neurogenesis in the
dentate gyrus [3]. Our results further suggest that the stimulating
action of fluoxetine on Wnt3a may not be dependent on BDNF (or
Figure 3. Effect of treatment with K252a icv for either the first or second 7 days of a 14 day fluoxetine (10 mg/kg/day) treatment.
A: Ki67-labelled cell counts; B: Wnt3a expression in the dentate gyrus. Values as in Figure 1. Bar represents 100 mm.
doi:10.1371/journal.pone.0013652.g003
BDNF and Neurogenesis
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receptor), so there may be other pathways linking the action of this
drug to neurogenesis in the dentate gyrus. The ability of fluoxetine
to increase Wnt3a is consistent with this drug’s reported induction
of neural plasticity [45,46,47]. This may well contribute to its
efficacy as an anti-depressant.
The experiments reported here emphasise the central role of
BDNF in the regulation of mitosis of the progenitor cells in the
dentate gyrus of the adult rat, and its contribution in the latent
period preceding the effect of fluoxetine on this process. The role
of BDNF in the expression of pCREB and Wnt3a may be
distinct. Our results further suggest that the control of the
neurogenetic niche may be widespread throughout the dentate
gyrus, though the identity of the cells that produce BDNF is still
obscure. They do not add directly to the evidence linking adult
neurogenesis with depression, but strengthen understanding of the
role of BDNF and its receptor in the action of anti-depressants
such as fluoxetine.
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